BTIG cuts target to USD 125.00 for Abbott Laboratories stock

Published on 10/26/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales reached USD 13.01 billion in the third quarter, up 14.5 percent. Abbott Laboratories stock costs EUR 92.58 on October 26, 2026 versus EUR 91.88.

Guidance and market context

On October 21, 2026, BTIG cut its target from USD 134.00 to USD 125.00.
Third-quarter sales reached USD 13.01 billion, up 14.5 percent year over year.
Abbott Laboratories stock trades at EUR 92.58 at 10:58 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.76 percent above the Xetra close of October 23, 2026.

Modernes Diagnostik-Labor Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) saw BTIG cut its price target from USD 134.00 to USD 125.00 on October 21, 2026, while the company reported third-quarter sales of USD 13.01 billion, up 14.5 percent from a year earlier. According to Investing.com, BTIG retained its Buy rating while lowering the target.

Guidance puts growth under review

Yahoo Finance reported on October 21, 2026 that Abbott posted third-quarter GAAP diluted earnings per share of USD 0.53 and adjusted diluted earnings per share of USD 1.42, compared with USD 1.30 a year earlier on an adjusted basis. Abbott narrowed full-year 2026 adjusted diluted earnings per share guidance to USD 5.50-5.55 and projected fourth-quarter adjusted diluted earnings per share of USD 1.62-1.67.

The revenue outlook is the pressure point. Abbott projected full-year comparable sales growth of 6.00 percent, while third-quarter comparable sales growth was 7.00 percent. That 1.00 percentage-point gap helps explain why BTIG focused on softer near-term growth in Electrophysiology and Diabetes.

Three dates explain the shift

On March 23, 2026, Abbott completed its Exact Sciences acquisition, which added cancer diagnostics to the portfolio. On September 17, 2026, the board declared a USD 0.63 quarterly dividend. On October 21, 2026, Abbott released third-quarter results and tightened its adjusted earnings range, according to Yahoo Finance.

What dates matter next?

The next dated corporate event is the USD 0.63 dividend payment scheduled for November 16, 2026, according to the same Abbott release. The company also indicated that fuller 2027 guidance would come in January 2027, without naming a specific day.

Stock holds above the Xetra close

Abbott's primary listing is on the NYSE, where the stock closed at USD 103.70 on October 23, 2026. Its market capitalization was USD 179.4 billion at that date, while the Lang & Schwarz quote was EUR 92.58, 0.76 percent above the Xetra close of October 23, 2026 at EUR 91.88.

At Lang & Schwarz, Abbott Laboratories stock was trading at EUR 92.58 on October 26, 2026 at 10:58 a.m. CEST, 0.76 percent above the Xetra close of October 23, 2026 at EUR 91.88. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.